Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gerald Greer

Internal Medicine Kokomo, IN Medical Doctor

NPI 1700882701 CMS profile 582503

2401 Columbus Blvd, Kokomo, IN 46901

Open in the dashboard

General payments

$9,036

415 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gerald Greer of Kokomo, IN is reported in the CMS Open Payments database as having received $9,036 across 415 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,252 64
2024 General $919 33
2023 General $1,635 48
2022 General $1,649 47
2021 General $482 26
2020 General $1,297 59
2019 General $1,802 138

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gerald Greer
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Gerald Greer were reported at $1,252. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Gerald Greer Internal Medicine median Middle half National median
2019 $1,802 $159 $48–$570 $163
2020 $1,297 $119 $33–$402 $114
2021 $482 $135 $37–$521 $132
2022 $1,649 $141 $42–$496 $149
2023 $1,635 $149 $45–$519 $160
2024 $919 $154 $47–$537 $164
2025 $1,252 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,506 60 payments
  2. Lilly USA, LLC $869 34 payments
  3. Novo Nordisk Inc $752 64 payments
  4. Otsuka America Pharmaceutical, Inc. $735 27 payments
  5. Allergan Inc. $579 42 payments
  6. Axsome Therapeutics, Inc. $544 11 payments
  7. AstraZeneca Pharmaceuticals LP $531 16 payments
  8. Corcept Therapeutics $347 15 payments
  9. Teva Pharmaceuticals USA, Inc. $280 5 payments
  10. Idorsia Pharmaceuticals US Inc $263 3 payments
  11. Other $2,629 138 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,929 406 payments
  2. Education $107 9 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $838 32 payments
  2. REXULTI $631 25 payments
  3. Auvelity $544 11 payments
  4. VRAYLAR Neuroscience $462 30 payments
  5. MOUNJARO $375 6 payments
  6. Saxenda $352 28 payments
  7. Korlym $347 15 payments
  8. FARXIGA $330 11 payments
  9. UBRELVY $303 6 payments
  10. QUVIVIQ $263 3 payments
  11. Other $5,669 312 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

857

Median for Internal Medicine: 777

Drug cost

$79,720

Median for Internal Medicine: $73,373

Branded share of claims

15.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 28 $29,063
Trulicity Dulaglutide Brand 25 $24,707
Mounjaro Tirzepatide Brand 12 $13,108
Jardiance Empagliflozin Brand 12 $7,106
Levothyroxine Sodium Generic 30 $653
Diclofenac Potassium Generic 22 $634
Albuterol Sulfate Hfa Albuterol Sulfate Brand 30 $567
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 11 $547
Amlodipine Besylate Generic 94 $332
Trazodone Hcl Generic 56 $252

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Auvelity
  • Axsome Therapeutics, Inc. $240
$240 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $192
  • Lundbeck LLC $14
$207 — —
Korlym
  • Corcept Therapeutics $150
$150 — —
VRAYLAR
  • AbbVie, Inc. $83
$83 — —
MAVYRET
  • AbbVie, Inc. $51
$51 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

415 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record